Oral focused remedy shrinks tumors in over 70% of sufferers with HER2-mutant NSCLC

The oral focused remedy sevabertinib led to tumor discount and manageable uncomfortable side effects in sufferers with HER2-mutant non-small cell lung most cancers (NSCLC), in response to knowledge from a trial led by researchers at The College of Texas MD Anderson Most cancers Middle. 

The Part I/II SOHO-01 medical trial discovered that over 70% of the sufferers studied noticed their tumors shrink or disappear. The outcomes have been revealed immediately within the New England Journal of Medication and offered concurrently on the European Society for Medical Oncology (ESMO) Congress 2025 (Summary LBA75) by principal investigator Xiuning Le, M.D., Ph.D., affiliate professor of Thoracic/Head and Neck Medical Oncology.

Why is the SOHO-01 research necessary?

Whereas platinum-based chemotherapy and, in some circumstances, immunotherapy are the usual first-line remedies for sufferers with superior HER2-mutant NSCLC, alternatives stay to enhance outcomes and decrease toxicity with new focused therapies. 

One such remedy, trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate (ADC), has acquired Meals and Drug Administration (FDA) accelerated approval for sufferers who’ve already been handled. Nonetheless, this remedy comes with well being dangers, together with interstitial lung illness (ILD). 

The trial outcomes counsel sevabertinib, a reversible tyrosine kinase inhibitor developed by Bayer – focusing on mutant HER2 whereas avoiding results on regular EGFR – could also be a protected and efficient choice for this affected person group. 

For sufferers with HER2-mutant lung most cancers, remedy choices have traditionally been restricted and outcomes suboptimal. FDA approval of sevabertinib would introduce one other focused remedy choice, one which exactly targets this mutation. This drug has demonstrated significant medical exercise with a manageable security profile, representing a big advance within the care of this difficult illness.”

Xiuning Le, M.D., Ph.D., affiliate professor of Thoracic/Head and Neck Medical Oncology

What are the important thing findings of the Part I/II SOHO-01 trial?

The open-label, multicenter SOHO-01 research enrolled 209 sufferers with superior NSCLC pushed by EGFR or HER2 into three completely different cohorts, every receiving 20 mg. of sevabertinib twice a day. Cohort D included 81 sufferers who had acquired prior remedy not focused to HER2; Cohort E included 55 sufferers who had acquired HER2-targeted ADCs; and Cohort F enrolled 73 sufferers who had not acquired prior therapies. 

The outcomes demonstrated sevabertinib decreased tumor exercise in sufferers each naïve to and beforehand handled with HER2-targeted antibody-drug conjugates. Diarrhea was the most typical facet impact, and no ILD was reported.

Of the subgroups, Cohort D sufferers had a response charge of 70.5%, with a median time of 8.3 months earlier than their most cancers progressed. Encouragingly, comparable outcomes have been seen throughout completely different affected person cohorts, regardless of which remedies they’d had earlier than or whether or not their most cancers had unfold to the mind.

Is sevabertinib at the moment authorised to be used in NSCLC sufferers? 

In Could 2025, sevabertinib was granted precedence evaluation for accelerated approval by the FDA. This got here after it acquired the FDA’s 2024 Breakthrough Remedy designation. The outcomes of SOHO-01 assist the New Drug Approval (NDA) submitted to the FDA.